Original Article | Published:

Chronic Myeloproliferative Neoplasias

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis

Leukemia volume 29, pages 13441349 (2015) | Download Citation

Abstract

We investigated the influence of molecular status on disease characteristics and clinical outcome in young patients (40 years) with World Health Organization (WHO)-defined essential thrombocythemia (ET) or early/prefibrotic primary myelofibrosis (early-PMF). Overall, 217 patients with ET (number 197) and early-PMF (number 20) were included in the analysis. Median follow-up time was 10.2 years. The cumulative incidence of thrombosis, hemorrhages and disease evolution into myelofibrosis/acute leukemia were 16.6%, 8.6% and 3% at 15 years, respectively. No differences were detectable between ET and early-PMF patients, although the latter cohort showed a trend for worse combined-event free survival (EFS). Mutation frequency were 61% for JAK2V617F, 25% for CALR and 1% for MPLW515K, and were comparable across WHO diagnosis; however, JAK2V617F allele burden was higher in the early-PMF group. Compared with JAK2V617F-positive patients, CALR-mutated patients displayed higher platelet count and lower hemoglobin level. CALR mutations significantly correlated with lower thrombotic risk (9.1% versus 21.7%, P=0.04), longer survival (100% versus 96%, P=0.05) and better combined-EFS (86% versus 71%, P=0.02). However, non-type 1/type 2 CALR mutations (‘minor’ mutations) and abnormal karyotype were found to correlate with increased risk of disease evolution. At last contact, six patients had died; in five cases, the causes of death were related to the hematological disease and occurred at a median age of 64 years (range: 53–68 years). Twenty-eight patients (13%) were unmutated for JAK2, CALR and MPL: no event was registered in these ‘triple-negative’ patients.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , . Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. Haematologica 2010; 95: 1038–1040.

  2. 2.

    , , , , , et al. Clinical manifestations of essential thrombocythemia in young adults. Am J Hematol 1990; 33: 27–31.

  3. 3.

    , , , , , et al. CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. Blood 2014; 123: 3677–3679.

  4. 4.

    , , , , , et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. Am J Hematol 2014; 89: 306–309.

  5. 5.

    , , , , , et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010; 149: 352–375.

  6. 6.

    , , , , , et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood 2012; 120: 569–571.

  7. 7.

    , , , , , et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391–2405.

  8. 8.

    , , , , , et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379–2390.

  9. 9.

    , , , , , et al. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia. Ann Hematol 2014; 93: 2029–2036.

  10. 10.

    , , , , , et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014; 123: 1544–1551.

  11. 11.

    , , , , , et alAssociazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014; 123: 1552–1555.

  12. 12.

    , , , , , et al. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica 2014; 99: 1184–1190.

  13. 13.

    , , , , , et al. Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients. Haematologica 2014; 99: e182–e184.

  14. 14.

    , , , , , et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia 2014; 28: 2300–2303.

  15. 15.

    , , , , , et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.

  16. 16.

    , . Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-ofcare diagnostic algorithms. Leukemia 2008; 22: 14–22.

  17. 17.

    , . Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 2010; 85: 62–69.

  18. 18.

    , , , , , et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013; 368: 22–33.

  19. 19.

    , , , , , et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437–438.

  20. 20.

    , , , , , et alWHO Classification of Tumours of Haematopoietic and Lymphoid Tissues4th ednIARC: Lyon, 2008, 127–129.

  21. 21.

    , , , , , et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia 2013; 27: 2032–2039.

  22. 22.

    , , , , . Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms. J Clin Pathol 2014; 67: 176–178.

  23. 23.

    , , , , , et al. The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia 2011; 25: 1840–1848.

  24. 24.

    , , . ISCN 2009: International System of Human Cytogenetic Nomenclature. Karger AG: Basel, Switzerland, 2009.

  25. 25.

    , , , , , et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29: 3179–3184.

  26. 26.

    , , , , , . Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 2011; 117: 5710–5718.

  27. 27.

    , , , , , et al. Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. Am J Hematol 2012; 87: 203–204.

  28. 28.

    , , , , , et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117: 5857–5859.

  29. 29.

    , , , , , . Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol 2011; 90: 933–938.

  30. 30.

    , , , , , et al. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood 2012; 120: 2704–2707.

  31. 31.

    , , , , , et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J 2010; 24: 665–683.

  32. 32.

    , . Getting in and out from calnexin/calreticulin cycles. J Biol Chem 2008; 283: 10221–10225.

  33. 33.

    , , , , , et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia 2014; 29: 249–252.

  34. 34.

    , , , , , et al. Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 2014; 89: e121–e124.

  35. 35.

    , , , , , et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120: 5128–5133.

Download references

Acknowledgements

This study was supported by BolognAIL, ELN, AIRC, progetto Regione-Università 2010-2012, FP7 and NGS-PTL Project.

Author Contributions

FP designed the research, analyzed data and wrote the paper. RL, NP, AT, MC and BM collected the data and gave the final approval. MP and EO performed molecular analysis. NT performed cytogenetic analysis. FM, FA, GA, MC, GM, LC, MB and NV reviewed the paper and gave the final approval.

Author information

Affiliations

  1. Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology ‘L. and A. Seràgnoli’, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy

    • F Palandri
    • , N Polverelli
    • , M Perricone
    • , E Ottaviani
    • , N Testoni
    • , M Cavo
    • , G Martinelli
    • , L Catani
    • , M Baccarani
    •  & N Vianelli
  2. Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy

    • R Latagliata
    • , M Breccia
    •  & G Alimena
  3. Division of Hematology, Azienda Ospedaliera Arcispedale Santa Maria Nuova, Reggio Emilia, Italy

    • A Tieghi
    •  & F Merli
  4. Section of Hematology and BMT Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy

    • M Crugnola
    •  & F Aversa
  5. Division of Hematology, Azienda Ospedaliera 'Bianchi Melacrino Morelli', Reggio Calabria, Italy

    • B Martino

Authors

  1. Search for F Palandri in:

  2. Search for R Latagliata in:

  3. Search for N Polverelli in:

  4. Search for A Tieghi in:

  5. Search for M Crugnola in:

  6. Search for B Martino in:

  7. Search for M Perricone in:

  8. Search for M Breccia in:

  9. Search for E Ottaviani in:

  10. Search for N Testoni in:

  11. Search for F Merli in:

  12. Search for F Aversa in:

  13. Search for G Alimena in:

  14. Search for M Cavo in:

  15. Search for G Martinelli in:

  16. Search for L Catani in:

  17. Search for M Baccarani in:

  18. Search for N Vianelli in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to F Palandri.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/leu.2015.87

Further reading